Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE versus INDERIDE 80 25.
Head-to-head clinical analysis: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE versus INDERIDE 80 25.
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE vs INDERIDE-80/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and further lowering blood pressure.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
1 tablet (candesartan cilexetil 16 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: 1 tablet (32 mg/25 mg) once daily.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
None Documented
None Documented
Candesartan: Terminal t1/2 ~9 hours (linear); clinically, once-daily dosing provides 24-hour antihypertensive effect. Hydrochlorothiazide: Terminal t1/2 ~6-15 hours (averaging 10 hours), prolonged in renal impairment.
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Candesartan: ~33% renal, ~67% biliary/fecal as unchanged drug and inactive metabolites. Hydrochlorothiazide: ≥95% renal as unchanged drug.
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Category A/B
Category C
Thiazide Diuretic
Beta Blocker and Thiazide Diuretic